Cancer Management & Treatment | Cancer Research & Drug Trials
Cancer Therapy Advisor offers the latest cancer management and treatment info, cancer research news, and more for oncologists and medical professionals.
Camrelizumab and Rivoceranib Improve Upon TACE in …
15 小时之前 · The median progression-free survival per RECICL was 10.8 months in the combination arm and 3.2 months in the TACE-alone arm. Adding camrelizumab and …
Neoadjuvant CRT and Immunotherapy: A New Standard of Care …
1 天前 · Neoadjuvant chemoradiotherapy (CRT) plus sintilimab yields a higher pathologic complete response (pCR) rate than neoadjuvant chemotherapy plus sintilimab in patients with …
Pamrevlumab Fails to Provide Survival Benefit in Locally Advanced ...
17 小时之前 · Adding pamrevlumab to chemotherapy does not improve survival outcomes in patients with previously untreated, locally advanced pancreatic cancer, according to results …
Aspirin Linked to Lower Risk of Recurrence in Certain CRC Patients
9 小时之前 · In patients with PIK3CA alterations in exon 9 and/or 20, the cumulative incidence of recurrence at 3 years was 7.7% in the aspirin arm and 14.1% in the placebo arm.
Cancer Management - Cancer Therapy Advisor
Cancer Therapy Advisor’s cancer treatment resources now include the most recent guideline-based information to inform oncologists and oncology professionals about therapy selection for …
Adjuvant T-DM1 Provides Long-Term Benefits Over Trastuzumab …
5 天之前 · At a median follow-up of 8.4 years, T-DM1 improved both invasive disease-free survival and overall survival. The trial (NCT01772472) included 1486 patients with HER2-positive early …
Antineoplastic Therapy: ASCO-ONS Standards Updated - Cancer …
2024年11月9日 · References: Siegel RD, LeFebvre KB, Temin S, et al. Antineoplastic therapy administration safety standards for adult and pediatric oncology: ASCO-ONS standards. JCO …
Breast Cancer Treatment & Pharmacologic Management
2023年5月17日 · Updated 9/24/2024. Breast cancer is the most common nondermal cancer in women, but it can also occur in men. The Surveillance, Epidemiology, and End Results …
May 2024: Oncology Drug Approvals - Cancer Therapy Advisor
2024年6月4日 · In May, the US Food and Drug Administration (FDA) approved a few drugs for cancer indications. The FDA granted first-time approval to tarlatamab-dlle (Imdelltra), …